Travere Therapeutics Q2 U.S. product sales up 70% to $161.4 million; net loss widens
Travere reported second quarter 2026 U.S. net product sales of $161.4 million, up from $94.8 million a year earlier, with FILSPARI sales growing 96% to $141.1 million. The GAAP net loss widened to $34.8 million, or $0.37 per basic share, mainly due to a $40.0 million inducement expense from 2029 convertible note repurchases, so strong sales growth is offset by a larger reported loss for shareholders.
Key points
- U.S. net product sales were $161.4 million in Q2 2026 versus $94.8 million in Q2 2025; FILSPARI accounted for $141.1 million.
- GAAP net loss was $34.8 million, or $0.37 per basic share, versus $12.8 million, or $0.14 per share, a year earlier.
- A $40.0 million inducement expense tied to 2029 convertible note repurchases in Q2 2026 drove much of the increase in other expense.
- In July 2026 the company closed the civorebrutinib in-licensing deal with Everest Medicines and made a $112.5 million upfront payment.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.